RenovoRx Appoints Ryan Witt as Senior Vice President, Head of Corporate Strategy and Partnerships

New role highlights RenovoRx’s commitment to explore and execute on clinical and commercial business development opportunities with its therapeutic technology

LOS ALTOS, CA – June 10, 2024RenovoRx, Inc. – (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a local drug-delivery platform, announced today that Ryan Witt has joined the Company in the new role as Senior Vice President, Head of Corporate Strategy and Partnerships.

Mr. Witt’s appointment highlights RenovoRx’s commitment to explore and execute on clinical and commercial business development opportunities not only for its RenovoGem™ investigational combination product (currently in Phase III clinical development), but also opportunities with the Company’s foundational FDA cleared drug-delivery device and other therapeutic agents.

Mr. Witt, who has been a consultant to the Company for the past year, has a strong track record, backed by 15 years of experience, in successfully leading corporate strategy in both medical technology and biopharmaceutical companies. Mr. Witt’s leadership in corporate strategy and operational experience includes sourcing, nurturing, negotiating, closing, and managing partnerships across top 25 global biopharma. Formerly, he was Chief Business Officer for Spinogenix, a series B funded, clinical-stage neuroregenerative biopharmaceutical company. Previously, Mr. Witt served as Chief Operating Officer at Immix Biopharma (NASDAQ: IMMX), Head of the Med Program at StartX, Medtech & Digital Health Innovation Hub Director at UCLA Biodesign, and Director of Product & Client Success at a health technology company funded by Novartis. In his spare time, Mr. Witt serves on Biocom’s Capital Development Committee where the team hosts Partnering Days with large multinational healthcare companies including Baxter, Bristol Myers Squibb, Daiichi-Sankyo, GSK, Novo Nordisk and Eli Lilly.

“I am thrilled to officially welcome Ryan as our new Senior Vice President, Head of Corporate Strategy and Partnerships,” said Shaun Bagai, CEO of RenovoRx. “Ryan brings extensive corporate strategy and operational experience to this role at RenovoRx.  He has already provided important value to our efforts, and we are excited to continue to leverage his expertise as we advance our pivotal Phase III clinical trial, expand development opportunities into additional cancers and explore new commercial business development opportunities with our therapeutic technology.”

“RenovoRx is at an important juncture, and I am excited to step into this role on a permanent basis,” said Mr. Witt. “Building off our collaboration with Imugene and clinical data delivering gemcitabine with our drug-delivery platform, there is incredible potential for RenovoRx’s technology. This is particularly apparent after my experience at Immix and working with over 200 leading Stanford-affiliated companies at StartX. I look forward to pulling from my experience in medical technology and biopharmaceuticals to help RenovoRx realize this opportunity in the form of better outcomes for patients and increased shareholder value.”

About RenovoRx, Inc.

RenovoRx is a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a local drug delivery platform for high unmet medical need with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx’s patented Trans-Arterial Micro-Perfusion (TAMP™) therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy’s toxicities versus systemic intravenous therapy. RenovoRx’s novel and patented approach to targeted treatment offers the potential for increased safety, tolerance, and improved efficacy. Our Phase III lead product candidate, RenovoGem™, a novel oncology drug-device combination product, is being investigated under a U.S. investigational new drug application that is regulated by the FDA’s 21 CFR 312 pathway. RenovoGem is currently being evaluated for the treatment of locally advanced pancreatic cancer (LPAC) by the Center for Drug Evaluation and Research (the drug division of FDA).

RenovoRx is committed to transforming the lives of patients by delivering innovative solutions to change the current paradigm of cancer care. RenovoGem is currently under investigation for TAMP therapeutic delivery of gemcitabine and has not been approved for commercial sale.

For more information, visit www.renovorx.com. Follow RenovoRx on FacebookLinkedIn, and Twitter.

Cautionary Note Regarding Forward-Looking Statements

This press release and statements of the Company’s management made in connection therewith contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934, including but not limited to statements regarding (i) our clinical trials and studies, including anticipated timing, statements regarding the potential of RenovoCath®, RenovoGem™ or TAMP™ or regarding our ongoing TIGeR-PaC Phase III clinical trial study in LAPC and future anticipated interim analyses from that study, (ii) the potential for our product candidates to treat or provide clinically meaningful outcomes for certain medical conditions or diseases and (iii) the anticipated benefits of Mr. Witt’s position with the Company as described herein.  Statements that are not purely historical are forward-looking statements. The forward-looking statements contained herein are based upon our current expectations and beliefs regarding future events, many of which, by their nature, are inherently uncertain, outside of our control and involve assumptions that may never materialize or may prove to be incorrect. These may include estimates, projections and statements relating to our research and development plans, intellectual property development, clinical trials, our therapy platform, business plans, financing plans, objectives and expected operating results, which are based on current expectations and assumptions that are subject to known and unknown risks and uncertainties that may cause actual results to differ materially and adversely from those expressed or implied by these forward-looking statements. These statements may be identified using words such as “may,” “expects,” “plans,” “aims,” “anticipates,” “believes,” “forecasts,” “estimates,” “intends,” and “potential,” or the negative of these terms or other comparable terminology regarding RenovoRx’s expectations strategy, plans or intentions, although not all forward-looking statements contain these words. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, that could cause actual events to differ materially from those projected or indicated by such statements, including, among other things: (i) circumstances which would adversely impact our ability to efficiently utilize our cash resources on hand or raise additional funding, (ii) the timing of the initiation, progress and potential results (including the results of interim analyses) of our preclinical studies, clinical trials and our research programs; (iii) the possibility that interim results may not be predictive of the outcome of our clinical trials, which may not demonstrate sufficient safety and efficacy to support regulatory approval of our product candidate, (iv) that the applicable regulatory authorities may disagree with our interpretation of the data; research and clinical development plans and timelines, and the regulatory process for our product candidates; (v) future potential regulatory milestones for our product candidates, including those related to current and planned clinical studies; (vi) our ability to use and expand our therapy platform to build a pipeline of product candidates; (vii) our ability to advance product candidates into, and successfully complete, clinical trials; (viii) the timing or likelihood of regulatory filings and approvals; (ix) our estimates of the number of patients who suffer from the diseases we are targeting and the number of patients that may enroll in our clinical trials; (x) the commercialization potential of our product candidates, if approved; (xi) our ability and the potential to successfully manufacture and supply our product candidates for clinical trials and for commercial use, if approved; (xii) future strategic arrangements and/or collaborations and the potential benefits of such arrangements; (xiii) our estimates regarding expenses, future revenue, capital requirements and needs for additional financing and our ability to obtain additional capital; (xiv) the sufficiency of our existing cash and cash equivalents to fund our future operating expenses and capital expenditure requirements; (xv) our ability to retain the continued service of our key personnel and to identify, and hire and retain additional qualified personnel; (xvi) the implementation of our strategic plans for our business and product candidates; (xvii) the scope of protection we are able to establish and maintain for intellectual property rights, including our therapy platform, product candidates and research programs; (xviii) our ability to contract with third-party suppliers and manufacturers and their ability to perform adequately; (xix) the pricing, coverage and reimbursement of our product candidates, if approved; and (xx) developments relating to our competitors and our industry, including competing product candidates and therapies. Information regarding the foregoing and additional risks may be found in the section entitled “Risk Factors” in documents that we file from time to time with the Securities and Exchange Commission.

Forward-looking statements included herein are made as of the date hereof, and RenovoRx does not undertake any obligation to update publicly such forward-looking statements to reflect subsequent events or circumstances, except as required by law.

Contact:

KCSA Strategic Communications
Valter Pinto or Jack Perkins
T: 212-896-1254
renovorx@kcsa.com

Previous Post
Publication of Results of Pre-Clinical Studies Support Efficacy and Drug Delivery Mechanism Potential of RenovoRx’s TAMP™ Therapy Platform to Improve Targeted Cancer Drug Treatment Deliver